Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

In addition to having tested over 150 beds altogether, we recently retested every bed on this list—along with dozens of others—to name the best mattresses of 2025.

Recently, a rare PML imaging pattern with punctiform enhancing lesions has been described in a patient with an asymptomatic course of natalizumab-associated PML.2 It remains unclear what this ...